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Introduction
In patients with advanced heart failure, the relief of symptoms is important. However, drugs such as milrinone, enoximone, and flosequinan have been shown to improve symptoms at the expense of an increase in fatality. [1] [2] [3] Thus, evidence that a new drug improves the symptoms of heart failure is necessary but not sufficient for its acceptance into clinical use. Ideally, a new drug would increase survival and improve symptoms; at the least, it should have no effect on survival.
Dopamine agonists have properties that make them potentially useful for the treatment of heart failure. Ibopamine is an orally active compound hydrolysed in vivo to epinine (N-methyldopamine). 4 The active metabolite stimulates DA-1 and DA-2 receptors and causes renal and peripheral vasodilatation, and does not seem to have an inotropic effect. 5 Previous studies showed that in patients with heart failure, ibopamine reduced plasma concentrations of noradrenaline, renin activity, and aldosterone. [6] [7] [8] Clinical studies have reported that ibopamine improves symptoms and has an effect similar to captopril on exercise tolerance in patients with mild-tomoderate heart failure. 9, 10 Ibopamine seemed to be a new class of drug that might make an important contribution to the management of patients with heart failure.
The Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II Study) was set up to investigate the effect of ibopamine on mortality and to collect sufficient data to show whether or not ibopamine treatment was safe.
Fatality rates among patients with severe heart failure are high, even if they receive optimum treatment. The PRIME II study was specifically designed to investigate the efficacy and safety of ibopamine in patients with advanced heart failure.
Methods
This multicentre, randomised study compared the effect of ibopamine 100 mg three times daily or placebo on all-cause mortality in patients with advanced heart failure. Secondary endpoints were cause of death, the need for cardiac transplantation, the number of and reason for hospital admissions, quality of life, symptom scores, and reasons for withdrawal from trial medication.
We used three methods for the assessment of patients' symptoms at each follow-up visit. The investigating physician applied the NYHA classification according to the patient's description of his or her symptoms. The patient's general state was assessed on a simple five-point scale-good, good/fair, fair, fair/awful, and awful. Orthopnoea, dyspnoea, peripheral oedema, and fatigue were assessed on individual four-point scales. In addition, a detailed quality-of-life assessment based on the Nottingham Health Profile 11 and on a disease-specific questionnaire 2 was completed by all participating centres in the Netherlands, the UK, and Italy at baseline and months 3 and 12.
Since previous studies suggested that ibopamine led to an improvement of symptoms in patients with heart failure, and because the drug was licensed in several European countries, the primary objective of our trial was to exclude the possibility that the hazard ratio for ibopamine treatment relative to placebo was 1·2 or higher. Based on the assumption of an annual mortality rate of about 20% with an average follow-up of 22 months, we calculated that 2200 patients would be needed for 80% power to show that the upper 95% confidence limit of the hazard ratio was less than 1·2. No interim analyses were planned, except as required by the safety committee.
All patients were included in the intention-to-treat analysis of survival. The hazard ratio was estimated by fitting of a proportional hazard regression model. This method was also used for post-hoc exploratory analysis of the effect of the treatment in various subgroups.
The study followed the terms of the Helsinki Agreement; the protocol was approved by the ethics committees of all participating centres. The trial was designed and supervised by a steering committee on which a statistician from the sponsoring company was present as a non-voting member. The steering committee was responsible for all scientific aspects of the study design, analysis, and reporting. The safety monitoring committee monitored the safety of ibopamine relative to placebo and had access to uncoded information. This committee had access to the data and was permitted to conduct any interim analysis deemed necessary. In addition, the committee took account of any new information that might become available during the trial. Stopping rules were pre-defined by the safety committee-the study would be stopped if there was conclusive evidence of a benefit from ibopamine (one-sided p<0·001, against placebo); if ibopamine was associated with an increase in mortality and the 98% CI excluded the possibility of a hazard ratio of 1·0 (ie, onesided p<0·01 against ibopamine treatment). The number of interim analyses was not prespecified, but these stopping rules are consistent with up to four or five interim analyses of the results at equal points during the follow-up. During the study, three formal analyses were done. Data on adverse events were reviewed every 3 months.
Patients were randomly allocated ibopamine or placebo by means of a numbered pack system within each centre. Duration of treatment was for a minimum of 6 months. Ibopamine and placebo were identical in all respects. The allocation schedule was computer-generated by the data centre in blocks of four. The main code was held by the safety committee and by the drugpackaging department (but no other department) of the sponsor. The pharmacy of each participating centre held a series of individual sealed envelopes that corresponded to the drug kits allocated to that centre and contained a code break for each kit. These envelopes were returned to the sponsor at the end of the trial so that maintenance of blinding could be checked. Each centre was supplied with drug kits with a unique number. At randomisation, the investigator used the kit with the lowest available number.
We recruited patients with advanced heart failure from participating centres in Europe which had varying access to detailed investigation of left-ventricular function. Thus, the inclusion criteria were described in general and specific terms. Our protocol stated that "The typical included patient either will have required hospital admission for advanced congestive cardiac failure, or will have had symptoms of congestive heart failure at rest despite optimal therapy, within the 2 months before randomisation. However, hospitalised patients who cannot realistically be expected to be discharged are not eligible for the study." In addition, we used the following specific inclusion criteria:
Limitation of activities-Breathlessness or fatigue because of heart failure. We defined advanced heart failure as New York Heart Association (NYHA) classes III and IV. Investigators could classify heart failure between classes III and IV as an intermediate class III/IV.
Optimum treatment for heart failure-Inhibitors of angiotensinconverting enzyme (ACE, unless tolerant), diuretics (furosemide 80 mg or more daily, if ACE inhibitors were not prescribed, or at least 40 mg daily in combination with an ACE inhibitor), and, if indicated, digoxin and other vasodilators.
Ev idenc e of heart disease-One of the following: left-ventricular ejection fraction (LVEF) of less than 35% on radionuclide or contrast ventriculography, or on echocardiography; left-ventricular internal diastolic diameter of more than 6 cm on echocardiography; fractional shortening of less than 20% on echocardiography; a cardiothoracic ratio of more than 50% on standard posteroanterior chest radiography.
Demography-Men or women aged 18-80 years.
Consent-All patients had to give written informed consent to take part in the study.
The exclusion criteria were: obstructive valve disease, obstructive or restrictive cardiomyopathy, any potentially transient cause of heart failure (eg, acute myocarditis), a myocardial infarction during the previous 3 months, unstable angina, uncontrolled arrhythmias, current need for intravenous inotropic support, intolerance of dopamine or ibopamine, concomitant use of medication known to interact with these drugs (eg, metoclopramide, levodopa), pregnancy or lactation, inadequate contraception in women of childbearing age, and administration of another investigational drug within the previous 30 days.
Minimum follow-up was for 6 months. Patients who were withdrawn were followed up every 3 months until the end of the study. We assessed patients at the initial screening visit, at week 4, and then every 3 months until the end of the study, by which time the patients who had been recruited first had taken the study medication for more than 3 years. Haematological and biochemical assessments were done at baseline, months 1, 3, and 6, and then every 6 months. Records were kept of concomitant medication and of the number, duration, and cause of hospital admissions. Left-ventricular function was assessed at baseline only. Continued=patients who took study medication until end of study or who died within 14 days of withdrawal. Discontinued=patients who were withdrawn from treatment and did not die within 14 days of last tablet, or who were not formally withdrawn but had not taken study medication within 14 days of end of study.
Data-handling under masked conditions was done at the Nottingham Clinical Trial Data Centre. Data were supplied to the safety committee on request. The treatment codes were held by the statistical representative of that committee. At the end of the study, the data centre was responsible for the statistical analyses on the instruction of the steering committee. A death classification committee, composed of representatives of the steering committee (AJC and FXK), who were unaware of treatment assignment, reviewed all available evidence on deaths. Deaths were classified according to the following criteria:
Sudden cardiac death-witnessed, instantaneous death in a patient who had no deterioration of heart failure for 1 week before death and no chest pain; or unwitnessed death in a patient who had no symptoms of heart failure for 1 week before death and no chest pain.
Progressive heart failure-shock, intractable heart failure that led to hospital admission, or deterioration of heart failure during the month before death.
Myocardial infarction-death during week after documented diagnosis of myocardial infarction, or death after suspected myocardial infarction.
Other cardiovascular death-cardiovascular deaths not covered by the above definition.
Results
The first patient was randomly assigned study medication in September, 1992. In August, 1995, the safety committee, at its regular meeting to review data then available, found a significantly higher fatality rate among ibopamine-treated patients than among placebo-treated patients. Thus, the safety committee advised the steering committee to terminate the study. All patients were subsequently withdrawn from treatment.
By August, 1995, we had recruited 1906 patients rather than the projected total of 2200, there were 953 patients in each group (figure 1). The patients were recruited from 192 centres in 13 European countries.
Baseline characteristics (table 1)
The treatment groups were well matched in terms of age, sex, and medical history. Current treatment for heart failure at baseline was also similar: the median diuretic dose (furosemide or equivalent) was 80 mg daily in both groups (mean 117 mg [range 40-1600]). Of the 463 (24%) patients who were currently taking antiarrhythmic drugs, 403 (87%) were on amiodarone.
The distribution of causes of heart failure was similar in the two groups. About 60% of patients had ischaemic heart disease and about 30% had dilated cardiomyopathy. In the ibopamine and placebo groups, 55% and 53%, respectively, had a history of myocardial infarction. In addition, the groups were well matched with respect to left-ventricular function. LVEF was measured by at least one method in 1748 (92%) patients, and the mean value in both groups was 26%. A measurement of cardiothoracic ratio on chest radiographs was available in 1741 (91%) patients, and the mean value was 58% in both groups. Left-ventricular internal diastolic diameter was measured by echocardiography in 1432 (75%) patients, and the mean diameter in each group was 6·9 cm. Table 1 shows that our protocol was successful in defining a group of patients with heart failure at high risk of death.
Fatality
Although recruitment stopped within a few days of the safety committee's decision to terminate the trial, further deaths were reported. The steering committee decided that the intention-to-treat analysis should be based on the number of deaths that occurred up to the time when patients were told to stop taking study medication; deaths after this time were censored. This analysis showed that 232 (24·3%) patients in the ibopamine group and 193 (20·3%) in the placebo group died during the study. This excess of 39 deaths in the ibopamine group was significant (log-rank test p=0·017) and the risk of death with ibopamine relative to placebo was 1·26 (95% CI 1·04-1·53). Figure 2 shows the proportion of patients who survived in each group. Survival seemed to be similar in both groups for the first 3 months, but thereafter the survival curves diverged to show a disadvantage with ibopamine treatment, which was most noticeable after 600 days. There was a significant difference in KaplanMeier estimates of 1-year mortality between ibopaminegroup patients and placebo-group patients who continued on treatment (19·5 vs 16·8%, p=0·017). Mortality rates in patients who were withdrawn from treatment were higher than those in patients who continued on treatment, but the difference between the ibopamine and placebo groups was not significant, because most withdrawals were made for clinical deterioration (25·3 vs 25·3%).
Overall, 21 patients in the ibopamine group and 22 in the placebo group underwent cardiac transplantation, of whom 13 and 16 had been previously withdrawn from the study. Of these 43 patients, two in the ibopamine group and seven in the placebo group died. All the patients who underwent cardiac transplantation were followed up until the end of the study; all deaths that occurred after transplantation were included in the intention-to-treat analysis. Study medication was discontinued before transplantation in some patients and at the time of surgery in others; for the on-treatment analysis these patients were classified as withdrawals. Alternative analyses that treated patients who underwent transplantation as censored observations or as deaths did not affect the significance levels. Table 2 shows the causes of death as determined by the death classification committee. There was no significant difference in the causes of death between the groups.
The average length of follow-up was 347 days in the ibopamine group and 363 days in the placebo group; few patients were followed up for more than 2 years. The estimated 1-year mortality rates were 23·7% in the ibopamine group and 20·8% in the placebo group.
Eight ibopamine-group patients and seven placebogroup patients were lost to follow-up whilst continuing on study medication. 259 patients (27%) in the ibopamine group and 222 (23%) in placebo group were withdrawn from study medication before death or before the end of the study; of these patients, 16 and 20, respectively, were lost to follow-up after they had been withdrawn from treatment. All other patients were confirmed to have died or were contacted by the centre after the end of the study.
185 ibopamine-treated and 141 placebo-treated patients were withdrawn because of adverse events; the excess of withdrawals in the ibopamine group was mainly due to gastrointestinal symptoms. Only three patients (two ibopamine, one placebo) were withdrawn because the investigator wished to use open-label ibopamine. The randomisation code was broken for eleven patients (four ibopamine, seven placebo).
The trial profile shows that at the time the study was stopped, 159 patients in the ibopamine group and 134 in the placebo group had died while on study medication or within 14 days of withdrawal from study medication (figure 1). Among the patients who continued to take study medication, four in the placebo group, compared with none in the ibopamine group died within 14 days of the end of the trial. These four patients are not included in Secondary outcome endpoints 442 (46%) of the patients in the ibopamine group compared with 416 (44%) patients in the placebo group were admitted to hospital during the trial (relative risk 1·13 [95% CI 0·99-1·29]; figure 3 ). 215 (23%) ibopamine-group patients and 203 (21%) placebo-group patients were admitted on more than one occasion; the causes of admission were similar in both groups. The patients' self-assessment scores of symptoms did not differ between the groups (table 3) . Similarly, there was no apparent difference between the groups in the investigators' assessment of NYHA function class, dyspnoea, orthopnoea, peripheral oedema, or fatigue (table 3) .
961 patients from the Netherlands, the UK, and Italy were included in the analysis of quality of life. There were no between-group differences in terms of the Nottingham Health Profile or the disease-specific questionnaire.
Subgroup analyses
Our study was not designed to assess the effect of ibopamine in any specific subgroup of patients, and no subgroups were identified a priori as being of particular interest. However, given the excess of deaths in the ibopamine group, we did various post-hoc analyses of subgroups to attempt to investigate the mechanism involved in this increased fatality.
Univariate analysis showed that the effect of ibopamine, relative to placebo, on mortality varied with subgroup for four factors: sex, NYHA class, duration of heart failure, and the use of antiarrhythmic drugs at entry to the study (p <0·1 in each group; table 4). For example, figure 4 compares survival in patients of NYHA class III and class III/IV by treatment group. Of the patients in NYHA class III, 97 (17·2%) of 564 ibopamine-group patients died versus 94 (16·4%) of 574 placebo-group patients (relative risk 1·06 [0·8-1·41]). By contrast, among patients of NYHA classes III/IV or IV, 135 (34·7%) of 389 ibopamine-group patients died versus 99 (26·1%) of 379 placebo-group patients (relative risk 1·48 [1·14-1·92]).
When the simultaneous effect of sex, NYHA class, duration of heart failure, and baseline use of antiarrhythmic drugs, was examined by multivariate analysis, the only factor that remained as an independent predictor of increased mortality from ibopamine was the use of an antiarrhythmic drug at baseline (figure 5).
Among the patients who did not use antiarrhythmic drugs at baseline, 172 (23·2%) of 740 ibopamine-group patients died versus 153 (21·8%) of 703 placebo-group patients (relative risk 1·1 [0·88-1·37]. By contrast, among those patients who used antiarrhythmic drugs at baseline, 60 (28·2%) of 213 ibopamine-group patients died versus 40 (16·0%) of 250 placebo-group patients (relative risk 1·95 [1·31-2·91]).
There were no significant subgroup effects for age, aetiology, previous morbidity, vital signs, LVEF, leftventricular internal diastolic diameter, carthiothoracic 
Discussion
This is the fourth major study to report an association between active treatment and increased fatality in patients with heart failure. 1-3 Nevertheless, the adverse effect of ibopamine on survival reported here was unexpected. Ibopamine has properties expected to confer benefit to patients with heart failure, particularly vasodilatation and an appropriate effect on neurohormones, and is also thought not to have inotropic effects. The drug is well established in several European countries for the treatment of heart failure, and no previous study or any postmarketing surveillance suggested the possibility that ibopamine might increase fatality.
Most previous studies of ibopamine were of short duration in patients with mild to moderate heart failure; PRIME II was not designed to investigate the effect of ibopamine on survival in such patients. By contrast, we included only patients with advanced failure. We do not know whether ibopamine is safe in patients with less advanced heart failure. Furthermore, because this study was not designed to assess the effect of ibopamine in different subgroups of patients, the results of our post-hoc subgroup analyses must be interpreted with caution, although the main adverse effect of ibopamine was seen in patients with NYHA class III/IV or IV.
The role of the safety monitoring committee was crucial in this study. The predefined stopping rules were asymmetric: a high probability of benefit from treatment was required before the study would be terminated (p<0·001), whereas the study would be stopped if ibopamine was harmful at a less significant level (p<0·01). These limits were chosen because of the widespread use of ibopamine in several European countries, where it is thought to be a clinically useful drug.
The only subgroup analysis requested by the safety committee was a comparison of the effect of treatment between patients who had NYHA class III and those with classes III/IV or IV. The safety committee was aware of the adverse effect of ibopamine in the patients with severe heart failure. Because there was no hypothesis that necessitated following the outcome in this, or in any other, subgroup, it was decided that the trial should continue if the adverse effect of ibopamine was limited to patients with severe heart failure and that the safety committee would recommend that the trial be stopped only if significant harm from ibopamine was shown in all patients, irrespective of NYHA class.
The mechanism underlying the adverse effect of ibopamine reported here is not known. Although subgroup analyses must always be viewed with caution, such analyses are a reasonable way of generating hypotheses when a trial is stopped early. Our post-hoc univariate analyses of various subgroups identified factors, particularly those linked to the severity of heart failure, that seemed to be associated with an unfavourable effect of ibopamine; and there was no difference between patients whose heart failure resulted from ischaemic heart disease and those with cardiomyopathy. In multivariate analysis, only the use of antiarrhythmic drugs at baseline emerged as an independent predictor for an adverse effect in ibopamine-treated patients. There is no known interaction between ibopamine and amiodarone or any other antiarrhythmic agent, and ibopamine is not thought to be proarrhythmic. 12 Since the subgroup of patients who received antiarrhythmics was identified as one of a wide variety of subgroups studied, and since there was no hypothesis about antiarrhythmic agents, the importance and underlying mechanism of this finding is unknown.
Two large substudies have been completed within the PRIME II protocol, but their results are not yet available. In one, the effect of ibopamine on a range of neurohormones was investigated: if the findings of this study support the results of previous investigations and show that the neurohormone profile is improved by ibopamine, the clinical results of PRIME-II may help define the importance of neurohormones in the progression of heart failure. The second substudy involves serial Holter electrocardiography monitoring, which should show whether ibopamine is proarrhythmic in patients with severe heart failure.
Restrictions have now been placed on the use of ibopamine in patients with severe heart failure in those countries where the drug is licensed.
